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Abstract
Beta-catenin plays an important role in embryogenesis and carcinogenesis by controlling either cadherin-mediated cell
adhesion or transcriptional activation of target gene expression. In many types of cancers nuclear translocation of beta-
catenin has been observed. Our data indicate that during melanoma progression an increased dependency on the
transcriptional function of beta-catenin takes place. Blockade of beta-catenin in metastatic melanoma cell lines efficiently
induces apoptosis, inhibits proliferation, migration and invasion in monolayer and 3-dimensional skin reconstructs and
decreases chemoresistance. In addition, subcutaneous melanoma growth in SCID mice was almost completely inhibited by
an inducible beta-catenin knockdown. In contrast, the survival of benign melanocytes and primary melanoma cell lines was
less affected by beta-catenin depletion. However, enhanced expression of beta-catenin in primary melanoma cell lines
increased invasive capacity in vitro and tumor growth in the SCID mouse model. These data suggest that beta-catenin is an
essential survival factor for metastatic melanoma cells, whereas it is dispensable for the survival of benign melanocytes and
primary, non-invasive melanoma cells. Furthermore, beta-catenin increases tumorigenicity of primary melanoma cell lines.
The differential requirements for beta-catenin signaling in aggressive melanoma versus benign melanocytic cells make beta-
catenin a possible new target in melanoma therapy.
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Introduction
The canonical Wnt/b-catenin signaling pathway plays a key
role in embryogenesis and cellular homeostasis and regulates cell
fate, differentiation, proliferation and self-renewal of stem cells and
progenitor cells. The activity of the central signaling molecule b-
catenin is mainly determined by regulation of proteolysis by the b-
catenin destruction complex including the principal constituents
casein kinase 1a (CK1a), glycogen synthase kinase 3 (GSK3),
adenomatous polyposis coli (APC) and axin [1,2]. In the absence
of Wnt pathway activation, cytosolic b-catenin is phosphorylated
and targeted for degradation. On Wnt stimulation the b-catenin
destruction complex dissociates, leading to an accumulation and
nuclear translocation of b-catenin, which is followed by binding to
the T cell factor/lymphocyte enhancer binding factor family
(TCF/LEF) and transcription of b-catenin/TCF/LEF responsive
genes [3]. Stabilization or nuclear translocation of b-catenin has
been observed in many types of cancers, such as colon, lung, skin,
breast, liver and pancreas cancers. Especially, truncating muta-
tions of the tumor suppressor APC are the most prevalent genetic
alterations in colorectal carcinomas [4].
Several studies have shown that the Wnt/b-catenin signaling
pathway regulates formation of neural-crest derived melanocytes
and by this influences melanocyte development [5,6]. Further-
more, in a transgenic mouse model it was shown that b-catenin
promotes immortalization of murine melanocytes by suppression
of the tumor suppressor p16INK4A and cooperates with N-Ras in
melanoma development [7,8]. In malignant melanoma, however,
there are contradictory results concerning the role of b-catenin in
tumor progression. Whereas several studies show nuclear accu-
mulation of b-catenin in at least 30% of melanoma cells [9–13]
and propose that an increased nuclear translocation and activity of
b-catenin promote melanoma proliferation [14,15], others found
that elevated levels of nuclear b-catenin correlate with improved
survival of melanoma patients [16] and that b-catenin downreg-
ulation promotes metastases formation in mice [17]. From these
data it has been proposed that canonical Wnt signaling via
activation of b-catenin is required for melanoma genesis, whereas
its continued expression in later stages inhibit metastases
formation. On the other hand, non-canonical Wnt signaling,
specifically Wnt5A, influences canonical pathways by downregu-
lation of b-catenin and signals to promote melanoma metastasis
[16–20].
We recently described that melanoma cells developed an
efficient new mechanism to activate the b-catenin signaling
pathway by suppression of CK1a expression, defining CK1a as
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23429a novel tumor suppressor in melanoma [21]. We observed that in
benign melanocytic cells and primary melanoma cells expressing
high levels of CK1a, b-catenin is mainly localized at the cell
membrane and that the free cytoplasmic and nuclear pools of b-
catenin increase during melanoma progression, in particular due
to downregulation or loss of CK1a expression. These studies
suggested that there is a differential dependency of benign
melanocytic cells and primary melanoma cells on b-catenin
concerning proliferation and survival. Based on these results we
asked in this study whether b-catenin fulfills different roles in
benign melanocytic cells and non-invasive primary melanoma and
metastatic melanoma cell lines.
Results
b-catenin is an essential survival factor for metastatic, but
not for primary melanoma cell lines and benign
melanocytes
We observed that RNA expression of the b-catenin target genes
fibronectin (FN1) and axin (Axn2) were upregulated in primary
melanomas and melanoma metastases compared to benign nevi
(Figure 1A). In a similar way metastatic melanoma cell lines
showed a higher RNA expression of both genes compared to non-
metastatic melanoma cell lines and normal human melanocytes
(NHM). Furthermore, b-catenin-TCF/LEF signaling activity was
higher in metastatic compared to non-metatastatic melanoma cell
lines as determined by a Super8xTOPflash reporter assay
(Figure 1A). These data suggest that the transcriptional activity
of b-catenin increases during melanoma progression.
To evaluate the role of b-catenin during melanoma progression
we downregulated b-catenin in several well-defined human
melanoma cell lines derived either from primary melanomas or
from melanoma metastases [22–24] using either a small-molecule
inhibitor of b-catenin/TCF/LEF complexes (PKF 115–584) [25]
or shRNA against b-catenin (Figure 1B). PKF115–584 treatment
of several melanoma cell lines and the colon cancer cell line
HCT116 as a control was not only able to downregulate b-catenin
transcriptional activity, but also b-catenin expression in a dose-
dependent manner (Figure S1A and S1B). Furthermore,
expression of either lentivirally delivered shRNA against b-catenin
or doxycycline-inducible knockdown of b-catenin using shRNA
efficiently reduced the amount of b-catenin protein (Figure S2A
and S2B). Inhibition of b-catenin expression and signaling in
metastatic melanoma cell lines (451LU, 1205LU, Mewo,
SKMel28) using PKF115–584 treatment resulted in a dose-
dependent reduction of viability (Figure 1B) accompanied with
morphological changes, such as rounding up and detachment from
the culture plate (data not shown). In contrast, the viability of
normal human melanocytes (NHMs) and the primary melanoma
cell lines WM35 and WM115 was completely unperturbed by the
inhibition of b-catenin (Figure 1B). To analyze whether
proliferation is affected we downregulated b-catenin using shRNA.
Here, a significant growth inhibition of metastatic melanoma cell
lines was measured up to 8 days post transduction with the
lentiviral shRNA, whereas the non-metastatic cell lines behaved
similiar to the non-silencing shRNA control transduced cells
(Figure 1B, Figure S4). Furthermore, knock down of b-catenin
expression in metastatic melanoma cell lines using doxycycline-
inducible shRNA significantly inhibited proliferation of the
metastatic melanoma cells lines SKMEL28 and 451LU
(Figure 1C). Finally, PKF115–584 treatment of melanoma cells,
freshly isolated and established from five different cutaneous
melanoma metastases, resulted in a concentration-dependent
inhibition of cell viability comparable to the effects observed in
the metastatic melanoma cell lines (Figure 1D). The PKF115–
584 concentrations which inhibit 50% of cell viability (IC50) are
summarized in Table 1. These data point out that b-catenin is an
essential survival factor for metastatic, but not for primary
melanoma cells and benign melanocytes.
b-catenin downregulation inhibits invasive tumor growth
of primary and metastatic melanoma cell lines
Next, we investigated whether b-catenin has an influence on the
migratory and invasive as well as the tumorigenic potential of
primary and metastatic melanoma cell lines. Downregulation of b-
catenin in six different metastatic and five primary melanoma cell
lines using PKF115–584 treatment resulted in a nearly complete
abrogation of migration and invasion using a Boyden chamber
assay with or without Matrigel as a substrate, whereas migration of
NHMs was not significantly affected after PKF115–584 treatment
(Figure 2A, Figure S5). Similarly, the inducible shRNA against
b-catenin strongly reduced melanoma cell migration and showed a
reduced invasiveness after shRNA induction compared to the non-
induced cells (Figure 2A). In addition, downregulation of b -
catenin by PKF115–584 treatment or by a doxycycline-inducible
shRNA against b-catenin inhibited metastatic melanoma cell
growth in a dermal environment and prevented invasive growth
through the basement membrane at the epidermal dermal
junction using an epidermal organotypic skin reconstruct
(Figure 2B). Furthermore, the tumorigenic potential of non-
metastatic (WM115, WM793) and metastatic (SKMel28, 451LU,
Mewo) melanoma cell lines in a soft agar growth assay was
efficiently inhibited in a PKF115–584 dose-dependent manner
(Figure 2C). We confirmed this by inducible expression of
shRNA against b-catenin in SKMel28 and 451LU cells
(Figure 2C). These data show that b-catenin downregulation in
primary and metastatic melanoma cell lines inhibit migration and
invasion in monolayer culture as well as in physiological skin
equivalents. Furthermore, it inhibits the tumorigenic potential of
non-metastatic and metastatic melanoma cell lines.
b-catenin expression influences melanoma cell growth in
vivo
To analyze the effect of b-catenin downregulation on growth of
melanoma cell lines in vivo, we subcutaneously injected 2610
5
451LU melanoma cells, in which b-catenin expression can be
inducibly knocked down by doxycycline treatment, into SCID
mice. 21 days later one group of mice received doxycycline in the
drinking water for 8 days, whereas the other group got normal
drinking water. Tumor volume was measured starting on day 24
for 14 days. As shown in Figure 2D downregulation of b-catenin
resulted in a nearly complete inhibition of tumor growth in vivo.
These data show that b-catenin downregulation in a metastatic
melanoma cell line inhibits melanoma cell growth in vivo.
To evaluate the functional effects of upregulated b-catenin
expression in primary melanoma cells we downregulated CK1a
expression in the non-metastatic, radial-growth phase melanoma
cell line SbCl2. As previously described by us [21] this results in a
stable upregulation of b-catenin protein level due to inhibition of
b-catenin degradation (Fig. 3A, E). This could not be achieved
after overexpression of wildtype b-catenin since it was rapidly
degraded (data not shown). Interestingly, whereas cell proliferation
in vitro was not affected by enhanced b-catenin expression in SbCl2
cells (Fig. 3B), matrigel invasion was significantly increased
(Fig. 3C). This effect could be reversed by simultaneous
downregulation of b-catenin using shRNA (Fig. 3C). More
importantly, tumor growth of SbCl2 cells subcutaneously injected
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23429Figure 1. b-catenin is a survival factor for metastatic, but not for primary melanoma cells and benign melanocytes. (A) b-catenin
signaling activity in melanoma samples: mRNA expression of the Wnt target genes fibronectin (FN1) and axin2 (Axn2) was measured in melanoma
tissue samples and benign nevi as well as in non-metastatic, or metastatic melanoma cell lines and normal human melanocytes (NHM) by real-time
PCR (normalized to b-actin). The canonical Wnt signaling activity in melanoma cell lines was assayed with the Super8xTOPFlash reporter plasmid.
Luciferase signals (RLU) were normalized to protein amount and measured in metastatic and non-metastatic melanoma cell lines (right diagram). Blue
bars: benign melanocytes, nevi and primary, non-metastatic melanomas; Red bars: metastatic melanomas. In melanoma metastases FN1 was found to
be significantly overexpressed compared to non-metastatic samples (p=0.045). Wnt reporter activity was significantly higher in metastatic compared
to non-metastatic melanoma cell lines (p=0.042). Significant differences are marked with asterisk (student t-test (95% CI)). (B) Influence of b-catenin
inhibition on viability/cell growth: Left panel: Normal human melanocytes (NHM), the primary melanoma cell lines WM35, WM115 (radial, non-invasive
growth phase) and WM793 (vertical, invasive growth phase) as well as the metastatic melanoma cell lines 451LU, SkMel28, 1205LU and Mewo were
assayed in a fluorescence cell viability test after three days of treatment with increasing concentrations of the small molecule PKF115–584. The colon
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catenin degradation (Fig. 3D). These data show that b-catenin
increases invasive capacity of primary melanoma cells in vitro and
tumor growth in vivo.
b-catenin downregulation induces apoptosis in
metastatic melanoma cell lines
To reveal the mechanism of cell death induced by b-catenin
downregulation in metastatic melanoma cell lines we analyzed
whether apoptosis is induced by b-catenin downregulation using
shRNAs or PKF115–584 treatment. Cell cycle analysis showed
that b-catenin downregulation leads to a reduced G2/M cell
population and the emergence of a subG1 fraction indicative for
apoptosis induction (Figure 4A, B). We confirmed apoptosis
induction by annexinV/PI staining and caspase 3 cleavage
(Figure S3A and S3B). Furthermore, inhibition of b-catenin
induced mitochondrial swelling and the mitochondria showed
degraded cristae indicating strong mitochondrial damage and
cytochrome C release (Figure 4C). In addition, PKF115–584
treatment reduced the expression of the anti-apoptotic proteins
Bcl-2, Mcl-1, Bcl-xL and the cell cycle regulator CyclinD1
(Figure 4D, Figure S1B).
b-catenin downregulation sensitizes melanoma cells
towards chemotherapy
Finally, we analyzed the effect of b-catenin downregulation in
metastatic melanoma cell lines on sensitivity towards the
chemotherapeutic agents temozolomide, cisplatin and doxorubicin
(Figure 5). Downregulation of b-catenin in 451LU and SKMel28
melanoma cells by shRNA (Figure 5A) or PKF-115–584
treatment (Figure 5B) significantly increased chemosensitivity
towards all three chemotherapeutics. Response surface analysis
[26] shows that the b -catenin inhibitor PKF115–584 acts
synergistically with the anti-cancer drugs. The effects after
PKF115–584 treatment are positioned above the surface of
additivity, i.e. the effects of combination treatment are super-
additive or synergistic (Figure 5B). These data indicate that b-
catenin is critically involved in chemoresistance of melanoma cells.
Discussion
In this study we show that b-catenin is an essential survival
factor for aggressive metastatic melanoma cell lines, but is
dispensable for proliferation of normal human melanocytes and
primary melanoma cell lines. Furthermore, we show that b-
catenin is a key factor determining invasive capacity and
tumorigenicity of primary and metastatic melanoma cell lines.
Finally, our data indicate that downregulation of b-catenin induces
apoptosis in metastatic melanoma cell lines and increases
chemosensitivity.
Several studies demonstrated that b-catenin activation is a key
step in the initial transformation of melanocytes to melanoma. In a
transgenic mouse model it was shown that b-catenin promotes an
escape of murine melanocytes from senescence by suppression of
the tumor suppressor p16INK4A resulting in melanocyte
immortalization. Interestingly, b-catenin cooperates with N-Ras
to promote melanoma development in mice [7]. Furthermore, it
was shown that cutaneous cancer stem cell maintenance is
dependent on b-catenin signalling [6,27]. Ablation of b-catenin
expression eliminated these stem cells and resulted in complete
regression of squamous cell carcinomas. Our data suggest that b-
catenin is a survival factor for metastatic, but not for primary
melanoma cell lines and benign melanocytes. This has not been
described so far, but there are reports demonstrating the necessity
of b-catenin signalling for the survival of epithelial mammary
gland cells [28] as well as in multiple myeloma [29]. Additionally it
is known that b-catenin regulates the expression of anti-apoptotic
Table 1. IC50 values (in nM) of PKF115–584 treated melanoma cell lines or primary cells (skin metastases or benign cells) calculated
using a non-linear regression analysis with variable slope.
Cell lines
non-metastatic metastatic
WM35 WM115 WM793 SKMel28 Mewo 1205LU 451LU
.2000 .2000 745 168 170 235 224
Primary cell cultures
Skin metastases Benign cells
#1 #2 #3 #4 #5 NHM Keratinocytes Fibroblasts
614 414 751 415 214 .2000 .2000 .2000
doi:10.1371/journal.pone.0023429.t001
cancer cell line HCT116 served as a control. Curve fits were calculated using a sigmoid dose response model with variable Hill slope. Right panel:
Shown is the time-dependent cell number (in % of control) after shRNA mediated downregulation of b-catenin. Lentiviral shRNA against b-catenin
was used to transduce the indicated cell lines. Due to the DsRed cassette in the lentiviral transfer plasmid, the fluorescence of transduced cells was
used for proliferation measurement starting 2 days after transduction. The fluorescence signal was normalized to the fluorescence signal of shluc
control transduced cells for every time point. NHMs and non-metastatic melanoma cell lines are marked in blue, non-metastatic melanoma cell lines
in red. (C) Doxycyline-inducible shRNA against b-catenin: Two clones, stably expressing a doxycycline-inducible shRNA against b-catenin were
generated from the parental cell lines SKMel28 and 451LU, induced with 1 mg/ml doxycycline and counted every 48 hours in triplicates to monitor
cell proliferation. The relative cell growth of the doxycycline induced samples compared to the non-induced populations are shown (normalized to
the number of seeded cells). (D) Pharmacological b-catenin inhibition in patient melanoma skin metastases: Five isolated melanoma cell populations
from melanoma skin metastases were tested in a fluorescence cell viability assay (MUH) after three days of treatment with increasing concentrations
of PKF115–584.
doi:10.1371/journal.pone.0023429.g001
b-Catenin as a Survival Factor in Melanoma
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23429Figure 2. Ablation of b-catenin activity in melanoma cells inhibits migration, invasion, the tumorigenic potential and melanoma
formation in vivo. (A) Migration and Invasion: NHMs and primary melanoma cell lines (left panel, blue bars) or metastatic melanoma cell lines
(middle and right panel, red bars) were used to perform Boyden-chamber experiments. Matrigel coated transwells were used to perform invasion
assays and non-coated transwells to assay the cell migration capability after treatment with 0.5 mM PKF115–584 for 12 hours (left and middle panel)
or the induced expression of shRNA against b-catenin for 24 hours (right panel), a time point at which there is no effect on cell viability as determined
by trypan blue staining. Shown is the percentage of migration or invasion compared to the control-treated cells. In each case the same number of
viable cells was applied to the chambers. Experiments were done in triplicates. All reductions in migration and invasion were significant except for
NHM (p,0.05). ND: not detectable. (B) Organotypic skin reconstruct: Organotypic dermal (451LU) or epidermal (SKMel28) skin reconstructs were
prepared from the metastatic 451LU or SKMel28 melanoma cells. Skin reconstructs were fixed, paraffine embedded and thin sections were stained
with hematoxylin/eosin to visualize melanoma cell nests. Arrows indicate invaded melanoma cells. Left panel: Dermal skin reconstruct with 451LU
cells. Skin reconstructs were treated with 0.5 mM PKF115–584 for seven days after an initial reconstruct cultivation time of 5 days. Right panel:
Epidermal skin reconstruct with SKMel28 cells expressing the doxycycline-inducible shRNA against b-catenin. Epidermal reconstrucs were treated for
10 days with 1 mg/ml doxycycline for shRNA induction. (C) Soft Agar Growth: Adhesion independent cell growth of the metastatic melanoma cell lines
SKMel28, 451LU or Mewo and non-metastatic cell lines WM115 and WM793 (left diagram) or the shbeta-catenin inducible cell clones (right diagram)
was measured in a 0.5% agar gel after 14 days of culture with increasing concentrations of PKF115–584 in the feeding layer. Colony numbers were
counted after 14 days. The assay was done in triplicates. (D) In vivo melanoma cell growth: 451LU melanoma cells expressing the doxycycline-
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Bcl- family [31]. We have found that depletion of b-catenin results
in reduced expression of the anti-apoptotic proteins Mcl-1 and
Bcl-xl showing the relevance of b-catenin for cell survival of
metastatic melanoma cells. On the other hand b-catenin was
recently found to have an additional function in microtubuli and
centrosome organization during mitosis [32–34].
We provide evidence that during melanoma progression the
transcriptional activity of b-catenin increases. It has been shown
that b-catenin plays a role both in the b-catenin/E-cadherin cell
adhesion complex and as a transcriptional regulator in the nucleus
upon canonical Wnt signalling [35]. It is well known that during
melanoma progression E-cadherin expression is lost [36] and as a
consequence of the disrupted high-affinity cadherin/b-catenin
interaction b-catenin is released to the cytoplasm and nucleus to
increase b-catenin transcriptional activity [37,38] This point out
that as soon as the cell adhesive pressure is lost, i.e. by loss of E-
cadherin expression, b-catenin is freed for its function in the
cytoplasm and nucleus and this pool is increased. This could
ultimately lead to loss of cell-cell-adhesion control, uncontrolled
growth and the capability to invade and metastasize.
In invasive breast cancer downregulation of membrane-
associated b-catenin results in decreased cell-cell adhesion and
increased motility resulting in a higher probability for metastatic
disease [39]. In melanoma there is evidence that activated b-
catenin is frequently found in migratory phenotypic melanoma
cells [40] and that b-catenin activation is important during
transendothelial migration of melanoma cell lines [41]. Indeed, we
find that b-catenin is essential for the invasive growth of primary
and metastatic melanoma cell lines.
PKF 115–584 has been originally described as a small-molecule
inhibitor of b-catenin/TCF/LEF complexes blocking the tran-
scriptional activity of b-catenin in the colon cancer cell line
HCT116, while b-catenin expression is not affected [25].
However, it was also shown that PKF115–584 treatment of
HCT116 disrupted not only the TCF/b-catenin complex, but also
interfered with APC/b-catenin complexes suggesting that expres-
sion of b-catenin might also be affected. Indeed, we describe that
treatment of several melanoma cell lines and HCT116 inhibit
both, b-catenin expression and transcriptional activity in a dose-
dependent fashion. More recent publications described also that
PKF115–584 treatment resulted in a dose-dependent reduction of
total beta-catenin protein levels in some acute myeloid leukemia
cell lines [42], smooth muscle cells [43] and mouse embryonic
fibroblasts [44]. All of the available data indicate that PKF115–
584 may be not a selective inhibitor of the TCF/beta-catenin
complex, but can inhibit also total beta-catenin protein levels.
It was proposed that an increased nuclear translocation and
activity of b-catenin promotes melanoma proliferation [14,15] and
could worsen the survival of melanoma patients [13]. On the other
hand, others found that elevated levels of nuclear b-catenin
correlate with improved survival of melanoma patients [16] and
that b-catenin downregulation promotes metastases formation in a
mouse model [17]. In our studies we find that the free cytoplasmic
and nuclear pools of b-catenin increase during melanoma
progression, which is then followed by a switch in b-catenin-
mediated signaling [21]. We suggest that early in melanoma
progression benign nevus cells and primary melanoma cells have a
b-catenin pool localized mainly at the cell adhesion complex
resulting in increased intercellular adhesion and limited invasive
growth potential. During melanoma progression the pool of
cytoplasmic and nuclear b-catenin protein levels increase mainly
due to loss of CK1a activity which results in a higher b-catenin
transcriptional activity [21]. Microphthalmia-associated transcrip-
tion factor (MITF) as one important transcriptional target of b-
catenin in melanoma cells could be critically involved in survival
and proliferation of metastatic melanoma cells with high b-catenin
transcriptional activity [15,45].
Altogether we propose that there is a differential dependency of
benign melanocytic cells and primary melanoma and metastatic
melanoma cell lines on b-catenin concerning proliferation and
survival. Targeting of b-catenin inhibits proliferation in all of the
metastatic melanoma cell lines tested and migration and invasion
of all melanoma cell lines tested (primary and metastatic), whereas
proliferation and migration of benign melanocytes are not
affected. Several other studies showed that the loss of b-catenin
in a number of differentiated cell types is compatible with normal
cell viability and tissue structure. Posthaus et al. showed that b-
catenin signaling is dispensable during proliferation and early
terminal differentiation of epidermal keratinocytes [46]. In
teratocarcinoma cells it was shown that the negative effect on
cell-cell adhesion by a loss of b-catenin is compensated by an
increased expression of plakoglobin [47]. First approaches for the
usage of the b-catenin inhibitor PKF115–584 in mouse models
showed no severe side effects [48–50] pointing out that targeting of
b-catenin is feasible and not toxic for the organism. We propose a
mechanism by which b-catenin’s transcriptional function gets
activated during melanoma progression and acts as a survival
signal in metastatic melanoma cells. Ablation of b-catenin’s
transcriptional activity induces downregulation of anti-apoptotic
genes, proliferation arrest and melanoma cell death. Furthermore,
we show for the first time a chemosensitizing effect of b-catenin
inhibition for two different chemotherapeutics in melanoma cell
lines. These findings make clear that b-catenin is a promising
candidate for novel approaches in the therapy of malignant
melanoma.
Materials and Methods
Cell Culture
Human metastatic melanoma cell lines were cultured in RPMI
1640 medium with 10% fetal bovine serum (FBS; Biochrom,
Berlin), penicillin and streptomycin. The non-metastatic melano-
ma cell lines were maintained in ‘‘2% Tumor’’ medium composed
of MCDB153:L15 (4:1) supplemented with 2% FBS and 5 mg/ml
insulin, unless otherwise stated. The isolation and culturing of
these cell lines have been described elsewhere [51,52]. These well-
defined human melanoma cell lines derived either from human
primary melanomas or from melanoma metastases recapitulate in
vitro and in vivo their biological behaviour of the original tumor cells
and are therefore representative members of melanoma cells in the
different progression stages [53,54]. The cell lines were kindly
gifted by M. Herlyn except for Mewo, SKMel28, SKMel19, MV3
and HCT116 which were purchased from ATCC [55]. Melano-
cytes, keratinocytes and fibroblasts were isolated from human
foreskin after routine circumcision. Melanocytes, fibroblasts and
inducible shRNA against b-catenin were injected into the flanks of 12 SCID mice which induced small tumor nodules after 3 weeks post injection. One
group received 200 mg/ml doxycycline into their drinking water for 7 days (from day 21 to day 28), whereas the control group received 0 ml/ml
doxycycline. Tumor growth was measured in total for 40 days post injection of the cells. Asteriks denote significant differences as measured by t-test
with one asteriks being p,0.05 and three asteriks being p,0.005 (t-test).
doi:10.1371/journal.pone.0023429.g002
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of the cell lines used in our study were authenticated by sequence
analysis of defined genes. The use and culturing of human skin
tissues in this study was approved by the medical ethical
committee of the University of Tu ¨bingen (43/2008B01; 16/
2009B02) and was performed in accordance with the Declaration
Figure 3. b-catenin expression determines melanoma cell growth in vivo. (A) Western Blot analysis of the non-metastatic melanoma cell line
SbCl2 after downregulation of CK1a by shRNA (or a non-silencing shRNA as control) with a lentiviral vector and subsequent selection of stable clones.
(B) The influence on proliferation was assayed by counting the cells every two days revealing no difference in cell growth in vitro.( C) Stable SbCl2
transductants were seeded onto a CIM plate (XCelligence DP; Roche), coated with Matrigel (1:10) for measuring invasion. The knockdown induced a
b-catenin dependent invasive cell growth through a matrigel matrix in the XCelligence DP system as indicated by the increase of the cell index (upper
right diagram). (D) Subcutanous injection of SbCl2 control cells or those in which b-catenin expression was upregulated by shRNA against CK1a into
SCID mice revealed a higher tumorigenicity and increased the tumor size by three fold (p=0.043). Shown is the mean tumor size (+/2 SD) 4 weeks
after injection of 2610
6 cells compared to the cells expressing a control shRNA (lower left diagram). Each dot indicates one tumor out of six mice. (E)
Immunohistochemistry of skin biopsies of mice at day 4 post injection with SbCl2 shCK1a cells showing viable, proliferating (Ki67) tumor cells (GFP
positive) with accumulated b-catenin (lower right picture).
doi:10.1371/journal.pone.0023429.g003
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consent.
Real-time PCR
All cell lines used for expression analyses were cultured 24 hours
before RNA extraction in the same medium (RPMI/10%FCS).
DNA-free total RNA was extracted with the NucleoSpin RNA II
kit (Machery-Nagel, Germany) and 1 mg RNA reverse transcribed
with Superscript II using hexamer primers into first strand cDNA.
The cDNA was used with the corresponding primers (designed
with the help of Primer3 and Universal Probe Library, Roche) into
a SYBR green real-time PCR and analyzed in a LightCycler480
(Roche, Mannheim, Germany) by the DDCt-method. The
following primer sequences were used:
Gene sense antisense
ACTINB ttgttacaggaagtcccttgcc atgctatcacctcccctgtgtg
FN1 gaataagctgtaccatcgcaaa tgtaaccaccagtctcatgtgg
AXN2 atgattccatgtccatgacg cttcacactgcgatgcattt
Luciferase Reporter Assay
Melanoma cells (3610
5 cells per well) were seeded in 6well plate
cavities and grown for 24 h. Cells were transfected using
Lipofectamin 2000 (Invitrogen, Heidelberg, Germany) with
2.0 mg Super8xTOPFlash and transferred into 96 well plates.
36 hours after transfection cells luciferase activity was measured in
lysates using the Dual Luciferase Reporter Assay (Promega) in a
TriStar luminometer (Berthold, Germany). RLU firefly values
were background subtracted and normalized to the protein
concentration of the lysate.
Organotypic skin culture
Organotypic skin reconstructs were prepared as described
previously [21,23,54]. Melanoma cells were either implemented
into the fibroblast containing dermal layer (as spheroids) or seeded
together with the keratinocytes as an epidermal layer.
Soft agar growth
Five thousand melanoma cells were seeded into each well of
12well plates together with 0.5ml of 0.5% agar noble (Difco,
Heidelberg, Germany) in melanoma cell growth medium. After
gelation, 1 ml of growth medium was applied on top and
inhibitors were added in the indicated concentrations into the
feeding 1 ml. Every treatment regimen was set up in triplicates.
After 14 days, the formed colonies were counted in every well and
photomicrographs were taken.
Migration and Invasion Assay
Migration and invasion assays were performed in Boyden
chambers coated with or without a Matrigel basement membrane
matrix (BD Biocoat Matrigel invasion chambers, BD Biosciences,
Heidelberg, Germany) as described previously [23]. Depending on
the cell line different cell numbers were subjected into the
transwell inserts. After incubation for 20 hours at 37uC the
invaded cells were fixed and counted after cell staining with
hematoxilin-eosin. The assays were performed in triplicates, six
fields were counted per transwell filter and mean cell numbers and
standard deviations were calculated.
Real-time invasion assay
The kinetics of cell invasion was assayed using the xCELLigence
Real-Time Cell Analyzer (RTCA DP; Roche). CIM-plate 16 wells
were pre-coated with 30 ml of matrigel diluted 1:10 in DMEM for
1 h at 37uC, then 10,000cells were plated in each well in fibroblast
conditioned serum-free DMEM. The lower medium chamber
contained fibroblast conditioned DMEM with 10% FCS. Cells
were allowed to settle for 30 min at room temperature before
being placed in the RTCA DP in a humidified incubator at 37uC
with 5% CO2. Readings were taken every 15 min for 24 h and
plotted curves represent the averages from three independent
wells/measurements.
In vivo melanoma growth assay
For the in vivo tumor growth assays, 8610
5 451LU cells stably
expressing tetracycline-inducible shRNA against b-catenin were
subcutaneously injected into SCID mice. 3 weeks post injection
small tumor nodules had developed in all the mice. One group was
subsequently fed with 200 mg/ml doxycycline in the drinking
water for one week. Tumor size was monitored for six weeks post
injection by measuring tumor length, width and height. The tumor
volume was calculated using the formula for ellipsoids (V=4/
3p*a*b*c). In case of subcutaneous injection of the radial growth
phase melanoma cell line SbCl2, 2610
6 cells were injected in
100 ul PBS with 10% matrigel into the flanks of the mice.
Subcutaneous tumor nodules were prepared four weeks post
injection and the tumor size was determined. All animal
experiments were approved by the Regierungspra ¨sidium Tu ¨bin-
gen (AZ HT6/06).
Lentiviral gene transfer
Lentiviral particles were produced in HEK 293T cells (Biocat,
Heidelberg, Germany) using the previously described transfer
plasmids of Skokowa et al. [58] and the second-generation
packaging and envelope plasmids pCMVDR8.2 and pMD2.G.
Melanoma cells were transduced with lentivirus containing
supernatants in the presence of 8 mg/ml polybrene and checked
for b-catenin knockdown by western blot 4 days after transduction.
Transmission electron microscopy
Cells were washed, centrifuged and the resulting pellets were
fixed for 24 hours in Karnovsky’s fixative (3% glutaraldehyde
(Sigma), 4% paraformaldehyde (Merck), 0.2 M Na-cacodylate
(Merck). After centrifugation, the sediment was embedded in 3%
agarose at 37uC and then cooled on ice. Post-fixation was based on
Figure 4. Inhibition of b-catenin induces apoptosis in metastatic melanoma cells. (A) Flow cytometric cell cycle analysis by propidium iodide
staining of the metastatic melanoma cell lines SKMel28, 451LU, Mewo, MV3, the primary melanoma cell lines WM1552 and WM3211 and NHM 48 hours
after PKF115–584 (1 mM) treatment. The percentage of the apoptotic subG1 fraction is indicated. (B) Cell cycle analysis of SKMEL28 melanoma cells 8
days after doxycycline-induced expression of shRNA against b-catenin. (C) SKMel28 cells were treated with PKF115–584 (1 mM) for 24 hours and either
stained for the mitochondrial marker cytochrome c oxidase IV (blue) and cytochrome c (red) plus nuclear staining with YOPRO (green) and analyzed by
confocal laser scanning microscopy (CLSM) (top panel) or subjected to transmission electron microscopy (TEM) (lower panel). In untreated cells COXIV
co-localizes with cytochrome c, whereas after treatment the COXIV is rarely detectable revealing either damaged mitochondria or cytochrome c release.
The electron microscopy revealed massive swollen (.2 fold) mitochondria which occurred already after 12 hours (data not shown). The mitochondria
showed degraded cristae and were only weekly electron-dense indicating strong mitochondrial damage. Asteriks/arrows indicate intact/damaged
mitochondria. (D) Western blot analysis of SKMel28 cells treated with increasing concentrations of PKF115–584 for 24 h for the known b-catenin target
genes Cyclin D1 and c-myc as well as the anti-apoptotic Bcl-family members Bcl-2, Bcl-xl and Mcl-1.
doi:10.1371/journal.pone.0023429.g004
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23429Figure 5. b-catenin increases chemoresistance of melanoma cells. (A) 451LU melanoma cells expressing the doxycycline-inducible shRNA
against b-catenin were treated with 1 mg/ml doxycycline and 24 hours later with increasing concentrations of the chemotherapeutics temozolomide,
cisplatin or doxorubicin for 72 hours. Cell viability was measured 96 hours after shRNA induction. Cell death was calculated out of the viability data
and compared to the control. (B) 451LU and SKMel28 melanoma cells were treated with increasing concentrations of PKF115–584 (0–1 mM) and the
three different chemotherapeutics temozolomide (0–600 mM), cisplatin (0–24 mM) and doxorubicin (0–2 mM) for 72 hours. Cell viability was assessed
and the mean values of three independent experiments were used for a response surface analysis to detect synergistic, additive or antagonistic drug
combinations. The measured effects were plotted together with the theoretical additive surface in a three dimensional coordination system (x:
PKF115–584; y: chemotherapeutic; z: cell death). At concentrations of PKF115–584 reducing b-catenin protein level, the combinations acted
synergistically. Asteriks denote significant differences as measured by t-test with one asteriks being p,0.05 and three asteriks being p,0.005 (t-test).
doi:10.1371/journal.pone.0023429.g005
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Aquadest for 2 hours. After embedding in glycide ether the blocks
containing cells were cut using an ultra microtome (Ultracut,
Reichert, Vienna, Austria) and ultra-thin sections (30 nm) were
examined using a Zeiss Libra120 transmission electron microscope
(Carl Zeiss, Oberkochen, Germany) operating at 120 kV.
Proliferation/Cell viability assay
For the analysis of proliferation and survival of melanoma cells,
2.5610
3 cells were seeded into 96-well plates and cultured for the
indicated periods of time. After washing, 4-methylumbelliferyl
heptanoate in PBS (100 mg/ml) was added and incubated for 1 h
at 37uC. Microplates were measured in a fluorescence microplate
reader (Berthold, Germany) with Ex355/Em460 nm in quintupli-
cates. In case of lentiviral shRNA transfer, the increase of DsRed
fluorescence which is expressed only in transduced cells was
measured from day 2 to day 6 using a microplate fluorescence
reader (Berthold, Germany). This fluorescence intensity correlates
in a linear way to cell number.
Apoptosis assays
Cell cycle analysis. 2610
5 cells were permeabilized in ice-
cold 70% ethanol for at least four hours and resuspended in 500 ml
PBS with 50 U RNAseA (Fermentas, St. Leon-Rot, Germany) and
50 mg/ml of propidium iodide (Sigma, Taufkirchen, Germany).
After 30 min cells were analyzed in a LSRII FACS (BD,
Heidelberg, Germany).
Mitochondrial staining. the following antibodies were used
as recommended by the manufacturer: anti-cytochrome c (BD
Biosciences, Heidelberg, Germany); anti-COX IV (Abcam,
Cambridge, UK).
AnnexinV-FITC/PI staining. After the indicated time of
culture, 1610
5 cells were resuspended in 50 ml binding buffer
(0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM CaCl2) containing
5 ml of AnnexinV-FITC (BD, Heidelberg, Germany) and stained
for 15 min. Then 10 mg/ml of propidium iodide (Sigma,
Taufkirchen, Germany) was added for 5 min and the cells were
analyzed in a LSRII FACS.
Caspase 3 activity assay
2610
4 cells were seeded into 96 well plates in quintuplicates,
treated as indicated and lysed in 50 ml caspase lysis buffer (20 mM
HEPES pH 7.4, 84 mM KCl, 10 mM MgCl2, 0.2 mM EDTA,
0.2 mM EGTA, 0.5% NP-40). 150 ml reaction buffer containing
50 mMHEPESpH 7.4,100 mMNaCl,2 mMCaCl2, 5 mMDTT,
10% sucrose, 0.1% CHAPS and 70 mM DEVD-AMC (Enzo Life
Sciences, Lo ¨rrach) were added to each well and fluorescence was
measured every 15 min for one hour in a Tristar microplate reader
(Berthold Technologies, Bad Wildbad) at Ex488 nm/Em512 nm.
Luciferase Reporter Assay
Melanoma cells (8610
4 cells per well) were seeded in 24well
plates and grown for 24 h. Cells were transfected using
Lipofectamin 2000 (Invitrogen, Heidelberg, Germany) with
0.4 mg Super8xTOPFlash. 36 hours after transfection cells
luciferase activity was measured using the Dual Luciferase
Reporter Assay (Promega) in a TriStar luminometer (Berthold,
Germany). RLU firefly values were background subtracted and
normalised to protein content.
Western Blot analysis
30 mg of lysate were subjected to SDS PAGE and blotted onto
PVDF membrane (Roche, Mannheim, Germany). The following
antibodies were used: anti-Mcl-1, anti-Bcl-xl (both from BD
Biosciences, Heidelberg, Germany), anti-Bcl-2, anti- b-catenin,
anti-Cyclin D1, anti-C-myc (Cell Signaling, Frankfurt, Germany),
anti- b-Actin, anti-CK1a and anti-LaminB (Santa Cruz, Heidel-
berg, Germany). For preparation of nuclear protein extracts the
cells were trypsinised and lysed in a hypotone buffer containing
0.5% NP-40. The detergent insoluble fraction containing nuclei
was further treated with a hypertone buffer. Semiquantification of
western blots was done with the freeware software tool scion image
(NIH image, http://rsb.info.nih.gov/nih-image/) by using the
actin signal as a reference.
Statistical analysis
Statistical analyses were performed with a two-tailed unpaired t-
test. P-values,0.05 were considered statistically significant.
Response surface analysis of melanoma cells treated with
combinations of pathway inhibitors and chemotherapeutic agents
was performed as previously described [26]. Briefly, the effects of
drug combinations (z axis) were plotted against the concentrations
of the single drugs (x-, y-axes). The surface representing additive
effects was developed with the dose-response data, curve fitted to
the hyperbolic equation: effect=(maximal effect6concentration)/
(maximal effect+concentration of half-maximal effect).
Supporting Information
Figure S1 (A) Pharmacological b-catenin inhibition
reduces b-catenin signaling and protein level in mela-
noma cells. SkMel28 melanoma cells were treated with 1 mMo f
the inhibitor PKF115–584 and nuclear b-catenin expression was
analyzed by confocal immunofluorescence microscopy over time
(nuclei: YOPRO-1 green; b -catenin: red) (left panel). In addition,
b-catenin-TCF/LEF signaling was determined by a Super8-
xTOPflash reporter assay. PKF115–584 inhibits the signaling in
a concentration dependent manner (right panel). Asteriks denote
significant differences as measured by t-test with one asteriks being
p,0.05, two asteriks being p,0.01 and three asterisk being
p,0.005 (t-test). (B) PKF115–584 treatment reduces pro-
tein levels of b-catenin, Cyclin D1, Mcl-1 and Bcl-xl.
Shown are western blot analyses of melanocytes (NHM), WM 35,
WM115, WM793, 451LU, 1205LU, Mewo and SKMel28
melanoma cells treated for 24 hours with increasing concentra-
tions of PKF115–584 (0–2 mM). Lysates were analyzed for
expression of b-catenin, cyclin D1, Mcl-1, Bcl-xl and actin. The
colorectal carcinoma cell line HCT116 served as a reference cell
line.
(TIF)
Figure S2 (A) Inhibition of b-catenin expression by
shRNA reduces b-catenin protein level in melanoma
cells. SkMel28 and 451LU melanoma cells were lentivirally
transduced with shRNA against b-catenin or luciferase as a
control. Total protein lysates were produced at the indicated time
points and 30 mg of lysate were subjected to a b-catenin western
blot (two top panels). On the right semiquantification of the
western blots (b-catenin protein expression normalized to actin) is
shown. (B) Inhibition of b-catenin expression by induc-
ible shRNA reduces nuclear b-catenin protein level. Two
clones stably expressing a Docycycline-inducible shRNA against
b-catenin were generated from the parental cell lines SKMel28
and 451LU with pcDNA6/TR and pTER-b-catenin. Both cell
lines were induced with 1 mg/ml doxycycline for the indicated
time points. Protein isolates of the induced clones revealed a b-
catenin downregulation in nuclear protein fractions after 4 days
(shown is the 451LU clone). As shown in the right diagram b-
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after doxycycline treatment in the clones expressing shRNA
against b-catenin.
(TIF)
Figure S3 PKF115–584 treatment induces apoptosis in
metastatic melanoma cells. (A) AnnexinV-FITC/PI staining:
SKMel28 melanoma cells were treated for 24–72 hours with
increasing concentrations of PKF115–584 (0–2 mM) and stained
with AnnexinV plus PI to detect apoptotic and necrotic cells in a
flow cytometry analysis. In a time and concentration dependent
manner the melanoma cells got AnnexinV positive (apoptotic)
before ending as AnnexinV and PI double positive dead cells.
Only a small amount of cells were necrotic as indicated by the
early appearance of AnnexinV/PI +/+ cells. (B) Caspase 3 activity:
451LU and SKMel28 melanoma cells were treated with 1 mM
PKF115–584 for 24 h or 48 h and cell lysates were used to
measure the DEVD-AMC cleavage activity as indicator for
activated caspase 3. The treatment induced a significant
(p,0.01) higher caspase activity of 10–30-fold, normalized to
untreated controls. A staurosporine treatment for 4 h served as a
positive control.
(TIF)
Figure S4 shRNA against b-catenin reduces melanoma
cell growth of metastatic melanoma cell lines (raw data
to Figure 1B). Different melanoma cell lines were lentivirally
transduced with shRNA against b-catenin or a non-silencing
control (both with RFP as a marker). The proliferation of the
metastatic melanoma cell lines 451LU, SKMel28, 1205LU and
Mewo ceased. Shown are the measured fluorescence values of
RFP expression of transduced cells over time, normalized to the
first day of measurement (day 2 after transduction). Increased RFP
values are indicative for an increase in cell number/cell
proliferation.
(TIF)
Figure S5 Ablation of b-catenin activity in melanoma
cells inhibits migration, invasion (raw data to Figure 2A).
Melanocytes (NHM) and non-metastatic melanoma cell lines or
metastatic melanoma cell lines were used for Boyden-chamber
experiments. Matrigel coated transwells were used to perform
invasion assays and non-coated transwells to assay the cell
migration capability after treatment with 0.5 mM PKF115–584
for 12 hours or after the induced expression of shRNA against b-
catenin for 24 hours. Cell viability was not affected as seen by
trypan blue staining. Shown is the number of counted cells per
field. All reductions in migration and invasion were significant
except for NHM (p,0.05).
(TIF)
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